



April 15, 2022

Dear HAE Community,

We are writing to share an exciting update regarding our efforts to bring a potential new treatment option to people living with hereditary angioedema (HAE). Ionis is enrolling the OASIS-HAE study, a global double-blind Phase 3 clinical trial evaluating the safety and efficacy of donidalorsen, an investigational antisense medicine being studied as a prophylactic treatment for HAE. Donidalorsen is designed to reduce the production of the prekallikrein (PKK) protein, which is believed to cause HAE attacks. Antisense medicines may be able to treat genetic diseases like HAE by targeting disease-causing proteins. To learn more about antisense medicines, please visit [ionispharma.com](https://www.ionispharma.com).

The OASIS-HAE study is expected to enroll about 80 people with HAE and last up to 46 weeks (about 10 months). The study will take place in sites across Europe and North America. Donidalorsen is self-administered via a subcutaneous injection every 4 or 8 weeks. For more details on the study, please visit: www.clinicaltrials.gov (NCT05139810), [OASIS-HAE.com](https://www.oasis-hae.com) or contact the OASIS-HAE study team directly at (844) 501-0233 and IonisOasisStudy@clinicaltrialmedia.com.

With the launch of the OASIS-HAE study, we are one step closer to potentially bringing a new and innovative therapy to people with HAE. We thank the patient advocacy organizations, the Hereditary Angioedema Association (HAEA), and the Hereditary Angioedema International (HAEi), for their partnership, as well as individuals with HAE who volunteer to participate in clinical research. It is only with the support and commitment of the patient community that we can advance potential new treatments for people with devastating diseases like HAE.

Sincerely,
The Ionis OASIS-HAE Study Team

For questions specific to participation in the OASIS-HAE study, please contact the OASIS-HAE study team at (844) 501-0233 or IonisOasisStudy@clinicaltrialmedia.com.

For patient questions about Ionis and our mission to develop a potential new treatment for HAE, please contact patients@ionisph.com.